Vial Logo

Next-Generation Pharma

Focused on advancing a pipeline of potentially best-in-class biologics and RNA therapeutics across areas of unmet need

Get in touch

Pipeline

TL1A HLE

Phase I
VIAL-TL1A-HLE has started a phase 1 trial and remains on track to have an interim data readout in 2Q25 and a final readout in 3Q25

Indication

Inflammatory bowel disease (IBD)

Next Data Catalyst

Interim data readout in 2Q25
Learn More Read Press Release
TL1A antibody diagram.

IL-13 x TSLP

Preclinical

Indication

Atopic Dermatitis, Asthma, Chronic Sinusitis

Est. Ph I Initiation

H2 2025

INHBE/Activin E

Preclinical

Indication

Obesity

Est. Ph I Initiation

H2 2025

a4B7 x IL-23

Preclinical

Indication

Inflammatory bowel disease (IBD)

Est. Ph I Initiation

H2 2025
Get in touch

Our model is powered by a computational discovery engine and highly automated clinical trials

Clip art of grey boxes with purple symbols and fake code
Clip art of grey boxes with purple symbols and fake code
molecule-icon

Computationally Enabled Discovery.

Computationally enabled discovery platform delivers programs with best-in-class, differentiated profiles at-scale.

Flowchart
Flow chart moving left to right showing the flow of records

Automated Clinical Trials.

Leveraging technology to automate clinical trials, enhancing precision and efficiency in drug development.

Recent Updates

Vial Announces Dosing of First Participants in Phase 1 Healthy Volunteer Trial of a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory and Fibrotic Diseases

Read Article

Vial Initiating Phase 1 Healthy Volunteer Trial of VIAL-TL1A-HLE, a Novel Subcutaneous Half-Life Extended Anti-TL1A Antibody for the Treatment of IBD and Other Inflammatory and Fibrotic Diseases

Read Article
View Updates

Stay updated on recent news and upcoming events.

Open Positions

Join our team in reimagining drug development.
Explore Roles